Ibandronic acid

Bezeichnung:Ibandronic acid

CAS-Nr114084-78-5

Englisch Name:Ibandronic acid

CBNumberCB4500836

SummenformelC9H23NO7P2

Molgewicht319.23

MOL-Datei114084-78-5.mol

Ibandronic acid physikalisch-chemischer Eigenschaften

Schmelzpunkt	113-115°C
Siedepunkt	587.8±60.0 °C(Predicted)
Dichte	1.449±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Löslichkeit	Aqueous Base (Slightly), Methanol (Slightly), Water (Slightly)
Aggregatzustand	Solid
pka	1.60±0.10(Predicted)
Farbe	White to Off-White
Stabilität	Hygroscopic
CAS Datenbank	114084-78-5(CAS DataBase Reference)
EPA chemische Informationen	Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis- (114084-78-5)

Gefahreninformationscode (GHS)

Ibandronic acid Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
This third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.
Chemische Eigenschaften
White Solid
Originator
Boehringer Mannheim (Germany)
Verwenden
A labeled biphosphonate bone resorption inhibitor.
Verwenden
Labelled Ibandronic Acid (I120000). A bisphosphonate antiresorptive agent. Bone resorption inhibitor.
Verwenden
A bisphosphonate antiresorptive agent. Bone resorption inhibitor.
Verwenden
A biphosphonate bone resorption inhibitor.
Trademarks
Bondronat
Clinical Use
Bisphosphonate:

Reduction of bone damage in bone metastases in breast cancer

Hypercalcaemia of malignancy

Postmenopausal osteoporosis
Stoffwechsel
After initial systemic exposure, ibandronic acid rapidly binds to bone or is excreted into urine. There is no evidence that ibandronic acid is metabolised in animals or humans. The absorbed fraction of ibandronic acid is removed from the circulation via bone absorption (estimated to be 40-50% in postmenopausal women) and the remainder is eliminated unchanged by the kidney. The unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces. Renal clearance accounts for 50-60% of total clearance and is related to creatinine clearance. The difference between the apparent total and renal clearances is considered to reflect the uptake by bone.

Ibandronic acid Upstream-Materialien And Downstream Produkte

Ibandronic acid Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

114084-78-5, Ibandronic acid Verwandte Suche:

Send Inquriy